TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. ("Antibe" or the "Company") (TSXV: ATE, OTCQX: ATBPF) is pleased to announce promising results from an independent bone loss study. A study directed by Dr. Marcelo Muscara at the University of Sao Paulo in Brazil provides compelling evidence that ATB-346, Antibe’s lead drug candidate for treating chronic inflammatory conditions such as osteoarthritis, has a superior safety profile as compared to conventional non-steroidal anti-inflammatory drugs (NSAIDs) in periodontal disease. NSAIDs, such as naproxen (Aleve), have well characterized adverse effects on bone growth. In the rat study performed by Dr. Muscara’s team, induction of periodontitis, an inflammation of the gums, was associated with a marked loss of alveolar bone, which is the thickened ridge of bone that contains the tooth sockets. When the rats were treated with ATB-346 for a week, there was a substantial improvement in the preservation of alveolar bone, while naproxen treatment made the bone loss worse. These results open up potential uses of Antibe’s drug candidates in the fields of regenerative medicine, orthopaedic and craniomaxillofacial surgery, where the adverse effects of NSAIDs on bone growth are an increasing concern.
Antibe’s CEO, Dan Legault commented, “The discovery by Dr. Muscara’s team of significant beneficial effects of ATB-346 in prevention of alveolar bone loss adds to our excitement about the strongly differentiated profile of our drug candidates, including the enhanced safety and tolerability that is imparted by the release of hydrogen sulfide from all of our drug development candidates. This discovery, together with our recent acquisition of Citagenix Inc., has Antibe poised to make significant contributions to the development of medications pertinent to regenerative medicine”.
As observed previously, treatment with naproxen also resulted in significant ulceration and bleeding in the stomach of the rats, while no damage was observed in rats treated with ATB-346. Dr. Muscara commented: “The hydrogen sulfide-releasing property of ATB-346 not only prevents tissue injury and bleeding in the stomach, it also markedly improves bone quality, suggesting that it may be a valuable new adjuvant therapy for periodontal disease”. The results of this study have been published in the journal Medical Gas Research (http://www.ncbi.nlm.nih.gov/pubmed/25755876).
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin.
Antibe is in the process of acquiring an 85% interest in Citagenix Inc., a Montreal-based sales and distribution company with a focus on regenerative medicine. This will create a diversified healthcare products company with annual revenues of approximately C$10 million and with commercial infrastructure for additional approved and higher-return, near-approval therapeutic products.
About Citagenix Inc.
Citagenix is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become the largest source of knowledge and experience in the Canadian medical device industry when it comes to bone regeneration and is known as a valuable reference and resource by clinicians. Operating in Canada through its direct sales teams, and a network of distributor partnerships around the world, Citagenix is active in 15 countries. For more information about the company, please visit http://www.citagenix.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Information
This news release includes certain forward-looking statements which may include, but are not limited to, the transition of the Company to a diversified healthcare company, the development of ATB-346 and other drugs, the thrust into regenerative medicine, the acquisition of shares of Citagenix, the completion of non-brokered private placement, opportunities for organic growth, growth of the business and revenue and the addition of products to the company’s product line. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, Citagenix financial performance not matching past performance, risks associated with drug development generally, failure to satisfy closing conditions for the Citagenix transaction and the private placement, not obtaining future financing on adequate terms, or at all, anticipated sales not achieving expected volumes and not obtaining TSX Venture Exchange approval for the transactions described herein. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.